PLEASE WAIT, LOADING

The use of semaglutide (Ozempic) in patients with heart failure

The use of semaglutide (Ozempic) in patients with heart failure

semaglutide-heart-attack-risk.jpg

The use of semaglutide (Ozempic) in patients with heart failure

In a recent study, presented at the European Society of Cardiology Heart Failure 2024 congress in Lisbon, it is nicely demonstrated that semaglutide (Ozempic) is beneficial in obesity related heart failure with preserved ejection fraction (HFpEF).

Semaglutide reduces the need for loop diuretics and has beneficial effects on symptoms, physical limitations, and body weight in this particular group of patients.

Additionally, it is found that semaglutide increases functionally capacity (6-minute walk test).

It is therefore demonstrated that this particular pharmaceutical agent has a significant role in the management of obese patients with HFpEF.

Reference:
https://www.escardio.org/The-ESC/Press-Office/Press-releases/Weight-loss-drug-linked-with-reduced-
need-for-diuretics-in-heart-failure-patients

Dr Yiannis Panayiotides


Dr_Yiannis_panagiotides_logo

Είναι αδύνατο να ξέρει την ιατρική, αυτός που δεν ξέρει ακριβώς τι είναι ο άνθρωπος. ΙΠΠΟΚΡΑΤΗΣ




Dr_Yiannis_panagiotides_logo

It is impossible for one to know medicine if he doesn’t know what a human being is. HIPPOCRATES






Copyright by Dr Yiannis Panayiotides 2018. All rights reserved.



Copyright by Dr Yiannis Panayiotides 2018. All rights reserved.